Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T17:08:59.881Z Has data issue: false hasContentIssue false
  • English
  • Français

Increased vascular endothelial growth factor expression predicts a worse prognosis for laryngeal cancer patients: a meta-analysis

Published online by Cambridge University Press:  08 December 2016

L-P Zhang  and
H-L Chen
L-P Zhang*
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, PR China
H-L Chen
Affiliation:
School of Nursing, Nantong University, PR China
*
Address for correspondence: Dr L-P Zhang, Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, 20 Xi Si Road, Nantong city, Jiangsu, 226001, PR China E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

This study assessed the relationship between vascular endothelial growth factor expression and the laryngeal cancer prognosis.

Methods:

Systematic computerised searches of PubMed were performed up to 31 January 2015. Prognostic endpoints were overall survival and disease-free survival. The pooled hazard ratios for overall survival and disease-free survival were also calculated.

Results:

Seven studies containing 975 patients were included. The pooled hazard ratio was 1.703 (95 per cent confidence interval, 1.373 to 2.112; z score = 4.85, p = 0.000) for overall survival and was 1.918 (95 per cent confidence interval, 1.410 to 2.609; z score = 4.15, p = 0.000) for disease-free survival. No significant publication bias was found. A sensitivity analysis showed that the results were robust. Power analyses also showed there was enough power to detect the calculated hazard ratios.

Conclusion:

The study found that vascular endothelial growth factor overexpression predicted a worse prognosis for laryngeal cancer patients. This supports a strategy of targeted therapy by blocking the vascular endothelial growth factor receptor.

Keywords

Laryngeal NeoplasmsVascular Endothelial Growth FactorsDisease-Free SurvivalSurvivalBiological Markers
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 131 , Issue 1 , January 2017 , pp. 44 - 50
Copyright
Copyright © JLO (1984) Limited 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29 Google Scholar
2 Torre, LA, Bray, F, Siegel, RL, Ferlay, J, Lortet-Tieulent, J, Jemal, A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108 Google Scholar
3 Jenckel, F, Knecht, R. State of the art in the treatment of laryngeal cancer. 2013;33:4701–10Google Scholar
4 Kim, NK, Park, JK, Shin, E, Kim, YW. The combination of nuclear factor kappa B, cyclo-oxygenase-2 and vascular endothelial growth factor expression predicts poor prognosis in stage II and III colorectal cancer. Anticancer Res 2014;34:6451–7Google Scholar
5 Li, T, Zhu, Y, Ren, W, Xu, S, Yang, Z, Fang, A et al. High co-expression of vascular endothelial growth factor receptor-1 and Snail is associated with poor prognosis after curative resection of hepatocellular carcinoma. Med Oncol 2012;29:2750–61CrossRefGoogle ScholarPubMed
6 He, W, Tang, B, Yang, D, Li, Y, Song, W, Cheang, T et al. Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients. World J Surg Oncol 2013; 18:161 Google Scholar
7 DeMei, M, XiangXin, L, YongPing, X, YongXia, Y, YunHai, Y, Lin, Z. Vascular endothelial growth factor C expression is closely correlated with lymph node recurrence and poor prognosis in patients with early stage cervical cancer. J Int Med Res 2013;41:1541–9Google Scholar
8 Chen, D, Zhang, YJ, Zhu, KW, Wang, WC. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol 2013;34:1895–9Google Scholar
9 Kyzas, PA, Cunha, IW, Ioannidis, JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005;11:1434–40Google Scholar
10 Huang, Q, Yu, GP, McCormick, SA, Mo, J, Datta, B, Mahimkar, M et al. Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: construction of oncogenetic trees for tumor progression. Genes Chromosomes Cancer 2002;34:224–33Google Scholar
11 Parmar, M, Torri, V, Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–34Google Scholar
12 Williamson, RP, Smith, TC, Hutton, JL, Marson, AG. Aggregate data meta-analysis with time-to-event outcome. Stat Med 2002;21:3337–51Google Scholar
13 Tierney, JF, Stewart, LA, Ghersi, D, Burdett, S, Sydes, MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16 CrossRefGoogle ScholarPubMed
14 Liu, Y, Su, Z, Li, G, Yu, C, Ren, S, Huang, D et al. Increased expression of metadherin protein predicts worse disease-free and overall survival in laryngeal cancer. Int J Cancer 2013;133:671–9Google Scholar
15 Pentheroudakis, G, Nicolaou, I, Kotoula, V, Fountzilas, E, Markou, K, Eleftheraki, AG et al. Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx. Oral Oncol 2012;48:709–16Google Scholar
16 Liu, Y, Qiu, Y, Zhang, X, Tian, Y, Huang, D, Zhou, X. The expression and correlation of HMGB1 and VEGF protein in laryngeal cancer. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2011;25:265–9Google Scholar
17 Rueda, A, Cazorla, O, Pérez, L, Álvarez, M, Redondo, M, Gallego, E et al. Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation. Head Neck 2011;33:808–16CrossRefGoogle ScholarPubMed
18 Parikh, RR, Yang, Q, Haffty, BG. Prognostic significance of vascular endothelial growth factor protein levels in T1–2 N0 laryngeal cancer treated with primary radiation therapy. Cancer 2007;109:566–73Google Scholar
19 Hinojar-Gutiérrez, A, Fernández-Contreras, ME, González-González, R, Fernández-Luque, MJ, Hinojar-Arzadún, A, Quintanilla, M et al. Intratumoral lymphatic vessels and VEGF-C expression are predictive factors of lymph node relapse in T1-T4 N0 laryngopharyngeal squamous cell carcinoma. Ann Surg Oncol 2007;14:248–57Google Scholar
20 Teknos, TN, Cox, C, Yoo, S, Chepeha, DB, Wolf, GT, Bradford, CR et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 2002;24:1004–11Google Scholar
21 Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581–611 Google Scholar
22 Roskoski, R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007;62:179–213 Google Scholar
23 Johnson, BF, Clay, TM, Hobeika, AC, Lyerly, HK, Morse, MA. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther 2007;7:449–60Google Scholar
24 Deezagi, A, Ansari-Majd, S, Vaseli-Hagh, N. Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA. Clin Transl Oncol 2012;14:791–9Google Scholar
25 Licitra, L, Bernier, J, Grandi, C, Locati, L, Merlano, M, Gatta, G et al. Cancer of the larynx. Crit Rev Oncol Hematol 2003;47:65–80 Google Scholar
26 Yoo, DS, Kirkpatrick, JP, Craciunescu, O, Broadwater, G, Peterson, BL, Carroll, MD et al. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res 2012;18:1404–14Google Scholar
27 Hainsworth, JD, Spigel, DR, Greco, FA, Shipley, DL, Peyton, J, Rubin, M et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium. Cancer J 2011;17:267–72Google Scholar